Pulmatrix, Inc.

Pulmatrix, Inc. announced a definitive merger agreement with Eos SENOLYTIX, Inc., under which Eos stockholders will own approximately 94% of the combined company, and Pulmatrix stockholders will own approximately 6%. Concurrently, Pulmatrix received a $1.0 million investment as part of a larger $19 million aggregate financing. For Q1 2026, the company reported a net loss of $(1.17) million, an improvement from $(1.81) million in Q1 2025, but faces substantial doubt about its ability to continue as a going concern without the merger.

Pulmatrix, Inc. announced its first quarter 2026 financial results and provided a corporate update, highlighting its merger agreement with Eos SENOLYTIX. The proposed merger, anticipated to close in Q3 2026, is a strategic move for the company. Pulmatrix also secured $1.0 million from a private placement of preferred stock and reported a reduced net loss of $1.17 million for Q1 2026, down from $1.81 million in Q1 2025. The company continues to focus on monetizing its iSPERSE™ technology and clinical assets.

Pulmatrix, Inc. announced the closing of its previously disclosed private placement of Series B Preferred Stock on April 16, 2026. The transaction was conducted under exemptions from registration requirements, specifically Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. A press release regarding the closing was issued on April 21, 2026.